NCT01148849View on ClinicalTrials.gov

Safety Study of MGAH22 in HER2-positive Carcinomas

PHASE1CompletedINTERVENTIONAL

Enrollment

66

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

June 14, 2022

Study Completion Date

June 14, 2022

Conditions

Breast CancerGastric Cancer

Interventions

BIOLOGICAL

margetuximab

margetuximab

Trial Locations (3)

20892

National Cancer Institute, Bethesda

37203

Sarah Cannon Research Institute, Nashville

110-744

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

Green Cross Corporation

All Listed Sponsors

collaborator

Green Cross Corporation

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

MacroGenics

INDUSTRY